Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II
Journal of Inherited Metabolic Disease · 2025-05 · 48 (3)
DOI: 10.1002/jimd.12790 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.09.2024. Verfasst von Joseph Muenzer und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Cognition, Iduronate Sulfatase, Mucopolysaccharidosis II. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Shire (a Takeda Company), Takeda Development Center Americas, Inc.
Abstract (Originalsprache)
Mucopolysaccharidosis II (MPS II; Hunter syndrome; OMIM 309900) is a rare, X‐linked, heterogeneous lysosomal storage disease. Approximately two‐thirds of patients develop cognitive impairment, which is difficult to assess in clinical trials, partly owing to the variable nature of cognitive impairment. Analyzing data from siblings can help to minimize this heterogeneity. We report analyses of cognitive function from siblings with MPS II enrolled in clinical trials: a natural history study (NCT01822184), a randomized, open‐label, phase 2/3 study of intravenous (IV) idursulfase with or without intrathecal idursulfase (idursulfase‐IT; NCT02055118), and its extension (NCT2412787). Cognitive function was assessed using Differential Abilities Scales, Second Edition General Conceptual Ability (DAS‐II GCA) scores; Bayley Scales of Infant and Toddler Development, Third Edition; and Vineland Adaptive Behavior Scales, Second Edition Adaptive Behavior Composite (VABS‐II ABC). Seven sets of siblings (six pairs and one set of three) were included. All patients received IV idursulfase and 10 received subsequent idursulfase‐IT. Younger siblings initiated IV idursulfase at an earlier age than their older sibling(s) in six of the sets; the younger sibling started treatment before 1 year of age in three sets. Monthly idursulfase‐IT was generally associated with a stabilization of cognitive function: DAS‐II GCA and VABS‐II ABC scores were higher at age‐matched assessments in the majority of those who either received idursulfase‐IT earlier than their sibling or who received idursulfase‐IT versus no idursulfase‐IT. These data suggest that early initiation of intrathecal enzyme replacement therapy may stabilize or slow cognitive decline in some patients with neuronopathic MPS II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.
- UCSF Benioff Children's Hospital Oakland, Oakland, California, USA.
- Infant Jesus Children's Hospital, Madrid, Spain.
- National Institute of Pediatrics, Mexico City, Mexico.
- St Mary's Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
Förderung
- NCATS NIH HHS
- Shire (a Takeda Company)
- Takeda Development Center Americas, Inc
Zitieren
APA
Muenzer, J., Burton, B. K., Harmatz, P., Gutiérrez-Solana, L. G., Ruiz-Garcia, M., Jones, S. A., Guffon, N., Inbar-Feigenberg, M., Bratkovic, D., Rust, S., Hale, M., Wu, Y., Yee, K. S., Whiteman, D. A. H., & Alexanderian, D. (2025). Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II. Journal of Inherited Metabolic Disease, 48(3). https://doi.org/10.1002/jimd.12790
Vancouver
Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, et al. Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II. Journal of Inherited Metabolic Disease. 2025;48(3). doi:10.1002/jimd.12790
BibTeX
@article{Muenzer2025,
author = {Muenzer, Joseph and Burton, Barbara K and Harmatz, Paul and Gutiérrez-Solana, Luis González and Ruiz-Garcia, Matilde and Jones, Simon A and Guffon, Nathalie and Inbar-Feigenberg, Michal and Bratkovic, Drago and Rust, Stewart and Hale, Michael and Wu, Yuna and Yee, Karen S and Whiteman, David A H and Alexanderian, David},
title = {Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {3},
doi = {10.1002/jimd.12790}
}
EUVIMED